Seer Inc
NASDAQ:SEER
Seer Inc
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. The company is headquartered in Redwood City, California and currently employs 118 full-time employees. The company went IPO on 2020-12-04. The firm enables scientific outcomes by commercializing products for researchers to unlock biological information. Its initial product, the Proteograph Product Suite (Proteograph), uses its engineered nanoparticle (NP) technology to provide access across the proteome. Its Proteograph Product Suite is comprised of consumables, an automation instrument and software. Its Proteograph provides a workflow, which enables proteomic profiling and the analysis of samples needed to characterize the nature of the proteome. The Company’s Proteograph consumables consist of its NP panel and other consumables necessary to assay samples on its SP100 automation instrument. Its SP100 automation instrument is custom-configured liquid handling workstation. The firm's Proteograph Instrument Control Software (PICS) for the SP100 instrument is fixed and designed to its specified workflow.
Revenue: Seer reported Q3 revenue of $4.1 million, up 2% year-over-year.
Instrument Demand: The company shipped nearly three times as many instruments in the first nine months of 2025 as in all of 2024, showing strong demand for the Proteograph platform.
Academic/Government Customers: About 40% of year-to-date revenue came from academic and government customers, but spending faces uncertainty due to macroeconomic headwinds and the government shutdown.
Partnerships: The Thermo Fisher partnership delivered its first joint sales in Q3, with a healthy pipeline and potential for more large-scale biobank opportunities.
Large-Scale Studies: Seer is supporting multiple major population studies and expects even bigger projects, predicting the first 100,000-sample mass spec study by 2026.
Gross Margin: Q3 gross margin improved to 51% from 48% a year ago, driven by higher consumable and service revenue.
Guidance: Full-year 2025 revenue is expected to be $17–18 million, but the company anticipates results at the lower end of the range due to ongoing customer budget and government funding constraints.
